A single contaminated batch of medicine can shut down a factory for weeks, but current tests take up to 14 days to spot the problem. GenomeKey is building a system that slashes that wait to just five hours by combining microfluidic cell concentration with next-generation DNA sequencing. The device processes large-volume manufacturing samples automatically: it concentrates and isolates microbial cells, extracts their DNA, and runs rapid sequencing analysis to identify contaminants at the strain level. This matters because pharmaceutical quality control still relies on culture-based methods that are slow and imprecise. A 14-day delay means a batch may already be packaged and distributed before contamination is detected, leading to costly recalls or patient harm. The new system offers real-time monitoring that could catch problems early, preventing batch losses and improving supply chain reliability. If successful, the technology could transform how medicines are manufactured. It integrates with existing good manufacturing practice infrastructure, so adoption is straightforward. Beyond speed, whole-genome sequencing reveals contamination sources and patterns, which could help regulators modernise their standards. The project positions the UK as a leader in next-generation pharmaceutical quality control, with strong export potential to global manufacturers.
View original technical description
GenomeKey is developing a revolutionary environmental monitoring system for pharmaceutical manufacturing that combines proprietary microfluidic concentration technology with next-generation DNA sequencing to enable rapid detection and identification of microbial contaminants. Current pharmaceutical quality control relies on traditional culture-based testing methods that require 6-14 days to detect contamination. Our innovation will reduce this to just 5 hours while providing superior strain-level identification capabilities. The system processes large-volume pharmaceutical manufacturing samples through an automated workflow that concentrates and isolates microbial cells, extracts DNA, and performs rapid sequencing analysis. This enables unprecedented speed and sensitivity in detecting potential contamination events during pharmaceutical production. The technology represents a step-change in manufacturing quality control, enabling real-time monitoring that could prevent costly batch losses through early contamination detection. Beyond accelerating testing, our whole-genome sequencing approach provides detailed insight into contamination sources and patterns. This capability will help drive regulatory modernisation in pharmaceutical manufacturing while delivering significant operational and cost benefits to end users. The system will integrate with existing pharmaceutical quality control infrastructure, enabling straightforward adoption within current good manufacturing practice environments. This innovation has potential to transform pharmaceutical environmental monitoring, supporting more efficient production of vital medicines while maintaining the highest quality standards. The project will establish UK leadership in next-generation pharmaceutical quality control technology with strong export potential to the global pharmaceutical manufacturing sector.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know